In December 2024, the Centre for Human Specific Research unveiled the Recombinant Antibodies and Mimetics Database – a pioneering platform offering researchers unprecedented access to high-quality, ethical affinity reagents. In a new article published by ATLA, Dr Stephanie Modi explores how this innovative database is driving the transition toward animal-free recombinant and mimetic antibodies, setting a new global benchmark for reproducibility, ethics, and progress in antibody science.
Antibodies in the Research Landscape
Antibodies are essential tools in biomedical science, but the widespread use of animal-derived products is associated with poor reproducibility and raises major ethical concerns. Studies show that up to half of commercial animal-derived antibodies fail to bind to their intended targets, wasting research funds and compromising the reliability of scientific findings. Recombinant antibodies and antibody mimetics offer a scalable, scientifically superior alternative, delivering greater consistency. Despite these advantages, they currently account for less than 5% of research reagents currently used, held back by limited awareness, access barriers, and misconceptions about their performance.
The Recombinant Antibodies and Mimetics Database
In the article, Dr Modi focuses on how the Recombinant Antibodies & Mimetics Database can help overcome some of these barriers by providing an open-access platform that links researchers to verified, ethically sourced affinity reagents. A unique colour-coded classification system clearly indicates the degree of animal involvement, empowering users to make informed choices. Beyond being a sourcing tool, the database also serves as a hub for advocacy – encouraging funders, institutions, publishers, and regulators to prioritise non-animal, sequence-defined antibodies. Dr Modi proposes that adopting non-animal-derived affinity reagents will not only improve reproducibility and reduce waste but also pave the way for a more ethical, sustainable, and scientifically rigorous future for antibody science.
‘The Recombinant Antibodies & Mimetics database empowers researchers to access sequence-defined affinity reagents that offer enhanced reproducibility, consistent batch performance, long-term renewability and ethical alignment, helping to establish recombinant antibodies and antibody mimetics as the new standard in research.’
Dr Stephanie Modi
The Future of Antibody Science
Beyond highlighting the benefits of recombinant antibodies and mimetics, and the utility of the database, Dr Modi calls for systemic policy changes to position recombinant and mimetic antibodies as the global standard. She proposes that funding agencies, journals, and institutions require transparent sourcing and sequence information for all antibodies used in research.